Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Often misunderstood and surrounded by myths, hemophilia is far more complex than most people think. From how it’s diagnosed ...

Hemlibra safely reduces bleeding episodes in people with hemophilia A without inhibitors, per a review study that confirmed ...

Discover how hemophilia A affects blood clotting, its genetic patterns, warning signs, advanced treatment options, and lifestyle modifications Skip to content News ...

Hemophilia is a rare genetic condition that keeps your blood from clotting, leading to bleeding problems. Bleeding can happen at any time (spontaneous) or as a result of trauma (injury, cut, or fall).

Hemophilia B is a rare X-chromosome-linked bleeding disorder caused by mutations in ... “The results of this important study are a perfect example of how UCL research and innovation can ...

People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of ...

For the study, researchers dosed 75 patients (mean age, 32.3 [19-59]; 100% men, 74.7% White and 18.7% Asian,) with hemophilia A with giroctocogene fitelparvovec, a hepatocyte-directed recombinant ...

The Food and Drug Administration (FDA) has approved Alhemo ® (concizumab-mtci) injection for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric ...

Pfizer’s hemophilia A gene therapy reduced annualized bleeding rates in a Phase 3 clinical trial, setting the stage for discussions with regulators. However, the market for such one-time ...